VRPX Virpax Pharmaceuticals Inc
Price (delayed)
$1.22
Market cap
$1.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$71
Enterprise value
-$216,803
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug
Highlights
The EPS has soared by 78% YoY and by 68% from the previous quarter
Virpax Pharmaceuticals's net income has increased by 21% YoY and by 9% from the previous quarter
The equity has plunged by 147% YoY but it has soared by 55% from the previous quarter
Virpax Pharmaceuticals's quick ratio has decreased by 49% YoY
Key stats
What are the main financial stats of VRPX
Market
Valuations
Earnings
Shares outstanding
1.06M
Market cap
$1.3M
Enterprise value
-$216,803
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.08M
Net income
-$12.07M
EBIT
-$11.96M
EBITDA
-$11.96M
Free cash flow
-$16.71M
Per share
Balance sheet
Liquidity
EPS
-$71
EPS diluted
-$71
Free cash flow per share
-$98.21
Book value per share
-$4.67
Revenue per share
$0
TBVPS
$9.14
Total assets
$1.56M
Total liabilities
$2.47M
Debt
$0
Equity
-$913,760
Working capital
-$913,760
Debt to equity
0
Current ratio
0.63
Quick ratio
0.61
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-636.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRPX stock price
How has the Virpax Pharmaceuticals stock price performed over time
Intraday
-4.69%
1 week
-21.29%
1 month
-79.67%
1 year
-98.83%
YTD
-87.16%
QTD
1.67%
Financial performance
How have Virpax Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.08M
Net income
-$12.07M
Gross margin
N/A
Net margin
N/A
VRPX's operating income is up by 23% year-on-year and by 10% since the previous quarter
Virpax Pharmaceuticals's net income has increased by 21% YoY and by 9% from the previous quarter
Growth
What is Virpax Pharmaceuticals's growth rate over time
Valuation
What is Virpax Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 78% YoY and by 68% from the previous quarter
The equity has plunged by 147% YoY but it has soared by 55% from the previous quarter
Efficiency
How efficient is Virpax Pharmaceuticals business performance
The ROA has plunged by 88% from the previous quarter
Dividends
What is VRPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRPX.
Financial health
How did Virpax Pharmaceuticals financials performed over time
The total assets is 37% less than the total liabilities
The total assets has plunged by 84% YoY
Virpax Pharmaceuticals's total liabilities has plunged by 68% YoY but it has increased by 4.8% from the previous quarter
Virpax Pharmaceuticals's debt is 100% more than its equity
The equity has plunged by 147% YoY but it has soared by 55% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.